Skip to main content
Fig. 5 | Journal of Neuroinflammation

Fig. 5

From: Anti-IgLON5 antibodies cause progressive behavioral and neuropathological changes in mice

Fig. 5

Anti-IgLON5 IgG-injected mice display microglial and astrocytic activation. A Immunofluorescence for IBA-1 (red) in anti-IgLON5 IgG-injected mice (right) compared to controls (left) on day 7. The higher magnification insets from the hippocampus show individual microglia. B Quantification of IBA-1 positive cell densities in the total hippocampus on day 7 (t = 4.169, df = 6, p = 0.0059; unpaired t-test). C Immunofluorescence for GFAP (green) in anti-IgLON5 IgG-injected mice (right) compared to controls (left) on day 7. The higher magnification insets from the hippocampus show individual astrocyte. D Quantification of GFAP-positive cell densities in the total hippocampus on day 7 (t = 0.3880, df = 6, p = 0.7114; unpaired t-test). E Immunofluorescence for IBA-1 (red) in anti-IgLON5 IgG-injected mice (right) compared to controls (left) on day 30. F Quantification of IBA-1 positive cell densities in the total hippocampus on day 30 (t = 5.966, df = 8, p = 0.0003; unpaired t-test). G Immunofluorescence for GFAP (green) in anti-IgLON5 IgG-injected mice (right) compared to controls (left) on day 30. H Quantification of GFAP-positive cell densities in the total hippocampus on day 30 (t = 3.752, df = 8, p = 0.0056; unpaired t-test). Scale bars = 1000 µm (Inset, 200 µm). For A–D, n = 4 per group. For E–H, n = 5 per group. **p < 0.01, ***p < 0.001 vs control IgG group

Back to article page